The Alzheimer's disease neuroimaging initiative

Susanne G. Mueller, Michael W. Weiner, Leon J. Thal, Ronald C. Petersen, Clifford Jack, William Jagust, John Q. Trojanowski, Arthur W. Toga, Laurel Beckett

Research output: Contribution to journalReview article

504 Scopus citations

Abstract

With increasing life expectancy in developed countries, the incidence of Alzheimer's disease (AD) and its socioeconomic impact are growing. Increasing knowledge of the mechanisms of AD facilitates the development of treatment strategies aimed at slowing down or preventing neuronal death. AD treatment trials using clinical outcome measures require long observation times and large patient samples. There is increasing evidence that neuroimaging and cerebrospinal fluid and blood biomarkers may provide information that may reduce sample sizes and observation periods. The Alzheimer's Disease Neuroimaging Initiative will help identify clinical, neuroimaging, and biomarker outcome measures that provide the highest power for measurement of longitudinal changes and for prediction of transitions.

Original languageEnglish (US)
Pages (from-to)869-877
Number of pages9
JournalNeuroimaging Clinics of North America
Volume15
Issue number4
DOIs
StatePublished - Nov 1 2005

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Clinical Neurology

Fingerprint Dive into the research topics of 'The Alzheimer's disease neuroimaging initiative'. Together they form a unique fingerprint.

  • Cite this

    Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C., Jagust, W., Trojanowski, J. Q., Toga, A. W., & Beckett, L. (2005). The Alzheimer's disease neuroimaging initiative. Neuroimaging Clinics of North America, 15(4), 869-877. https://doi.org/10.1016/j.nic.2005.09.008